Alongside appreciating the nature of growth investing from a risk perspective, Ian Battersby argues it is critical advisers obtain comfort from providers over both deal-flow quality and deployment capability
So the dust is settling in the aftermath of the Patient Capital Review and Enterprise Investment Scheme (EIS) season is in full swing. The future is all about growth companies. It now seems to be accepted that EIS offers generous tax benefits for investments into qualifying growth companies - and yet what is the reality behind such a broad statement? The ‘lag' effect of the seven-year rule has started to have an impact on the open offers available in the market, with the age and maturity level of potential EIS investee companies showing a tendency towards earlier-stage companies and, in...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
